日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma

自泌素分泌是胰腺导管腺癌中基质细胞对TGFβ抑制剂产生适应性抵抗的机制

Silvia Pietrobono # ,Fabio Sabbadini # ,Monica Bertolini ,Domenico Mangiameli ,Veronica De Vita ,Federica Fazzini ,Giulia Lunardi ,Simona Casalino ,Enza Scarlato ,Valeria Merz ,Camilla Zecchetto ,Alberto Quinzii ,Giusy Di Conza ,Michael Lahn ,Davide Melisi

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

高选择性口服磷脂酰肌醇 3-激酶 delta (PI3K-δ) 抑制剂罗吉诺利布可诱导间皮瘤细胞凋亡并增加免疫效应细胞组成

Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti

Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models

自分泌运动因子抑制剂 IOA-289 在临床前模型中减缓胃肠道癌症进展

Matteo Centonze, Giusy Di Conza, Michael Lahn, Isabel Fabregat, Francesco Dituri, Isabella Gigante, Grazia Serino, Rosanna Scialpi, Livianna Carrieri, Roberto Negro, Elena Pizzuto, Gianluigi Giannelli

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

IOA-244 是一种非 ATP 竞争性、高选择性、耐受性好的 PI3K Delta 抑制剂,可靶向实体肿瘤并打破免疫耐受性

Zoë Johnson #, Chiara Tarantelli #, Elisa Civanelli, Luciano Cascione, Filippo Spriano, Amy Fraser, Pritom Shah, Tyzoon Nomanbhoy, Sara Napoli, Andrea Rinaldi, Karolina Niewola-Staszkowska, Michael Lahn, Dominique Perrin, Mathias Wenes, Denis Migliorini, Francesco Bertoni #, Lars van der Veen, Giusy

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

galunisertib 和 ramucirumab 治疗晚期肝细胞癌患者的 1b 期研究

James J Harding, Richard K Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A Benhadji, Robin K Kelley, Ghassan K Abou-Alfa

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

澳大利亚一项针对晚期或转移性癌症患者的卡瑞利珠单抗首次人体剂量探索研究

Jason D Lickliter ,Hui K Gan ,Mark Voskoboynik ,Surein Arulananda ,Bo Gao ,Adnan Nagrial ,Peter Grimison ,Michelle Harrison ,Jianjun Zou ,Lianshan Zhang ,Stacey Luo ,Michael Lahn ,Howard Kallender ,Andrea Mannucci ,Catello Somma ,Katherine Woods ,Andreas Behren ,Pablo Fernandez-Penas ,Michael Millward ,Tarek Meniawy

Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis

TGFβ 和 PDGF 信号联合抑制可减轻放射性肺纤维化

Monika Dadrich, Nils H Nicolay, Paul Flechsig, Sebastian Bickelhaupt, Line Hoeltgen, Falk Roeder, Kai Hauser, Alexandra Tietz, Jürgen Jenne, Ramon Lopez, Manuel Roehrich, Ute Wirkner, Michael Lahn, Peter E Huber

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

TGF-β 受体激酶抑制剂 galunisertib(LY2157299 一水合物)在患者来源的肿瘤异种移植中的抗肿瘤活性

Armin Maier, Anne-Lise Peille, Vincent Vuaroqueaux, Michael Lahn

Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma

TGFβR-I 激酶抑制剂 LY2109761 阻断 TGF-β 信号传导可增强放射反应并延长胶质母细胞瘤的生存期

Mengxian Zhang, Susanne Kleber, Manuel Röhrich, Carmen Timke, Na Han, Jochen Tuettenberg, Ana Martin-Villalba, Juergen Debus, Peter Peschke, Ute Wirkner, Michael Lahn, Peter E Huber

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

对复发性急性髓系白血病患者进行多激酶抑制剂 LY2457546 的剂量研究,以评估安全性、药代动力学和药效学

Volker Wacheck, Michael Lahn, Gemma Dickinson, Wolfgang Füreder, Renata Meyer, Susanne Herndlhofer, Thorsten Füreder, Georg Dorfner, Sada Pillay, Valérie André, Timothy P Burkholder, Jacqueline K Akunda, Leann Flye-Blakemore, Dirk Van Bockstaele, Richard F Schlenk, Wolfgang R Sperr, Peter Valent